Overview
FAQs
Research Feed
Update History
References2026-07-05
Page created majorIntervention page: glatiramer acetate as a Validated Pharmaceutical MBTI, immunomodulatory and antimicrobial mechanisms, Conditions table linking its validation page, FAQs, and Research Feed.
Did you know?
Copaxone, a first-line multiple sclerosis drug, turns out to be an antibiotic: it kills Gram-negative bacteria, the very group enriched in the MS gut signature. A depleted gut commensal, Prevotella histicola, matches its effect in animal models.
Glatiramer Acetate
Glatiramer acetate (Copaxone) is a random amino-acid copolymer used as an immunomodulatory drug whose mechanism also includes direct antimicrobial activity against Gram-negative bacteria.
Page Snapshot
Microbiome-targeted interventions (MBTIs) are validated using a dual-evidence logical framework. First, the intervention must realign the condition’s microbiome signature by increasing beneficial taxa that are consistently depleted and reducing pathogenic taxa that are consistently enriched. Second, the intervention must demonstrate measurable clinical benefit. Concordance of these effects in the same context validates the intervention as an MBTI and supports the clinical relevance of the microbiome signature.
Karen Pendergrass
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreOverview
Glatiramer acetate (Copaxone) is a synthetic random polymer of four amino acids, developed as an immunomodulatory drug. Its established use is as a disease-modifying therapy, and it is treated here as a microbiome-targeted intervention (MBTI) because, beyond immunomodulation, it has direct antimicrobial activity against Gram-negative bacteria, a group that features in several dysbiotic signatures.
Mechanism of Action
Glatiramer acetate was designed to shift T cells toward an anti-inflammatory profile and to act as a decoy for myelin basic protein. Independently, it is an effective antimicrobial peptide analogue that kills Gram-negative bacteria by disrupting their membranes.[1] These two mechanisms converge wherever Gram-negative Proteobacteria are part of the disease signature.
This antimicrobial activity targets Gram-negative Proteobacteria, including zinc-acquiring Pseudomonas.[1][2] The reciprocal evidence is striking: the gut commensal Prevotella histicola suppresses the MS animal model as potently as Copaxone, and Copaxone therapy raises Prevotella abundance, implying a shared microbiome-level mechanism.[3][4]
Conditions
Glatiramer acetate is a Validated disease-modifying therapy for relapsing multiple sclerosis, where its clinical benefit and its antimicrobial mechanism converge.
| Condition | Findings | MBTI Status |
|---|---|---|
| Multiple Sclerosis | A phase III randomized, double-blind, placebo-controlled trial showed a 29 percent reduction in relapse rate and improved disability over two years.[5] Mechanistic work ties part of the benefit to antimicrobial action against the signature's Gram-negative pathogens.[1][3] | Validated |
In the pivotal Copolymer 1 phase III trial, 251 people with relapsing-remitting MS received glatiramer acetate 20 mg subcutaneously daily or placebo for two years; the relapse rate fell 29 percent and more treated patients improved on the disability scale, with good tolerability aside from injection-site reactions and no immunosuppression-related infection risk.[5] The validation page details how this benefit, the antimicrobial mechanism, and the MS microbiome signature converge.
FAQs
What is Glatiramer Acetate?
Quick answer: Glatiramer acetate (Copaxone) is a synthetic random polymer of four amino acids, developed as an immunomodulatory drug. Its established use is as a disease-modifying therapy, and it is treated here as a microbiome-targeted intervention (MBTI) because, beyond immunomodulation, it has direct antimicrobial activity against Gram-negative bacteria, a group that features in several dysbiotic signatures.
How does Glatiramer Acetate work?
Quick answer: Glatiramer acetate was designed to shift T cells toward an anti-inflammatory profile and to act as a decoy for myelin basic protein. Independently, it is an effective antimicrobial peptide analogue that kills Gram-negative bacteria by disrupting their membranes. [1] These two mechanisms converge wherever Gram-negative Proteobacteria are part of the disease signature.
What conditions can Glatiramer Acetate help?
Quick answer: Glatiramer acetate is a Validated disease-modifying therapy for relapsing multiple sclerosis , where its clinical benefit and its antimicrobial mechanism converge.
Research Feed
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: a phase III trial
1995
The pivotal trial that established glatiramer acetate (Copaxone) as a disease-modifying therapy for MS.
What was studied?
Whether copolymer 1 (glatiramer acetate) reduces relapse rate and disability in relapsing-remitting multiple sclerosis.
Who was studied?
251 people with relapsing-remitting MS randomized to glatiramer acetate 20 mg subcutaneously daily or placebo for two years at eleven centers.
What were the key findings?
The relapse rate fell 29 percent versus placebo (p = 0.007), and significantly more treated patients improved on the disability scale, with good tolerability aside from injection-site reactions.
What are the implications?
Glatiramer acetate is an effective, well-tolerated disease-modifying therapy for relapsing MS, and remains first-line decades later.
Prevotella histicola is as potent as COPAXONE in an animal model of multiple sclerosis
2019
A gut commensal depleted in MS suppressed the animal model as effectively as the drug glatiramer acetate.
What was studied?
Whether the human gut commensal Prevotella histicola, depleted in MS, suppresses disease in the animal model as effectively as glatiramer acetate (Copaxone), and whether the two synergize.
Who was studied?
HLA-transgenic mice with experimental autoimmune encephalomyelitis, treated with P. histicola, Copaxone, both, or sham.
What were the key findings?
P. histicola suppressed disease as effectively as Copaxone; the combination was no better than either alone. P. histicola increased regulatory T cells and reduced IFN-gamma and IL-17-producing T cells.
What are the implications?
A depleted gut commensal reproduces a validated MS drug's effect, pointing to a shared microbiome-level mechanism and an alternative, microbiome-based treatment route.
Update History
References
- The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria. Christiansen SH, Murphy RA, Juul-Madsen K, et al. (Sci Rep. 2017)
- ZnuA and zinc homeostasis in Pseudomonas aeruginosa. Pederick VG, Eijkelkamp BA, Begg SL, et al. (Sci Rep. 2015)
- Prevotella histicola, A Human Gut Commensal, Is as Potent as COPAXONE in an Animal Model of Multiple Sclerosis. Shahi SK, Freedman SN, Murra AC, et al. (Front Immunol. 2019)
- Microbial monotherapy with Prevotella histicola for patients with multiple sclerosis. Mangalam AK, Yadav M, Yadav R. (Expert Rev Neurother. 2018)
- Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Johnson KP, Brooks BR, Cohen JA, et al. (Neurology. 1995)
Reference [1]
The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria.
Christiansen SH, Murphy RA, Juul-Madsen K, et al. Sci Rep. 2017
View sourceReference [2]
ZnuA and zinc homeostasis in Pseudomonas aeruginosa.
Pederick VG, Eijkelkamp BA, Begg SL, et al. Sci Rep. 2015
View sourceReference [3]
Prevotella histicola, A Human Gut Commensal, Is as Potent as COPAXONE in an Animal Model of Multiple Sclerosis.
Shahi SK, Freedman SN, Murra AC, et al. Front Immunol. 2019
View sourceReference [4]
Microbial monotherapy with Prevotella histicola for patients with multiple sclerosis.
Mangalam AK, Yadav M, Yadav R. Expert Rev Neurother. 2018
View sourceReference [5]
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial.
Johnson KP, Brooks BR, Cohen JA, et al. Neurology. 1995
View source